Bruce Booth Sells 606 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Key Points

• Director Bruce Booth sold a total of 606 shares of Sionna Therapeutics stock on October 14th for approximately $18,149.70, reducing his ownership by 0.08%.
• Sionna Therapeutics' stock hit $30.91 on October 15th, reflecting a significant increase from its one-year low of $7.26.
• Analysts have given Sionna Therapeutics a consensus rating of "Moderate Buy" with a target price of $38.00, amidst varying ratings from different investment firms.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Bruce Booth sold 606 shares of the business's stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $29.95, for a total transaction of $18,149.70. Following the transaction, the director owned 771,762 shares in the company, valued at approximately $23,114,271.90. The trade was a 0.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Bruce Booth also recently made the following trade(s):

• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.61, for a total transaction of $3,546,352.16.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.38, for a total transaction of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.98, for a total transaction of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total transaction of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total transaction of $372,383.28.
• On Monday, September 29th, Bruce Booth sold 66,105 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.09, for a total transaction of $1,989,099.45.

Sionna Therapeutics Price Performance

NASDAQ:SION traded up $0.97 during trading hours on Wednesday, hitting $30.91. 339,961 shares of the company traded hands, compared to its average volume of 213,803. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $31.47. The firm's 50-day simple moving average is $24.65 and its 200-day simple moving average is $18.12.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.27.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics in the second quarter valued at $31,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Sionna Therapeutics during the 2nd quarter worth approximately $45,000. Virtus Investment Advisers LLC purchased a new stake in Sionna Therapeutics in the 2nd quarter valued at approximately $96,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Sionna Therapeutics in the second quarter valued at $117,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Sionna Therapeutics during the 2nd quarter worth $118,000.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Raymond James Financial began coverage on Sionna Therapeutics in a research note on Tuesday, September 2nd. They issued a "strong-buy" rating and a $45.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Sionna Therapeutics in a research note on Wednesday, October 8th. Royal Bank Of Canada initiated coverage on Sionna Therapeutics in a report on Wednesday, September 3rd. They set a "sector perform" rating and a $22.00 price objective for the company. Wall Street Zen raised Sionna Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Finally, Jones Trading assumed coverage on Sionna Therapeutics in a research note on Monday, September 8th. They set a "buy" rating and a $46.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.00.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.